[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Fatnassi R, Amri F: [Adenosarcoma of the uterus: a case report]. J Gynecol Obstet Biol Reprod (Paris); 2005 May;34(3 Pt 1):270-2
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenosarcoma of the uterus: a case report].
  • Adenosarcoma of the uterus has two components: a benign epithelial proliferation and a stromal sarcoma.
  • The purpose of this work was to report the clinical aspects and therapeutic modalities of an exceptional case of uterine adenosarcoma in a 15-year-old girl revealed by pelvic pain.
  • Histology of the mass confirmed the diagnosis of adenosarcoma of the uterus.
  • The patient underwent hysterectomy and was given chemotherapy.
  • This rare tumor (8% of uterine sarcomas) generally requires hysterectomy.
  • [MeSH-major] Adenosarcoma / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Biopsy. Female. Humans. Hysterectomy. Pelvic Pain. Ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16012388.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Carvalho FM, Carvalho JP, Motta EV, Souen J: Müllerian adenosarcoma of the uterus with sarcomatous overgrowth following tamoxifen treatment for breast cancer. Rev Hosp Clin Fac Med Sao Paulo; 2000 Jan-Feb;55(1):17-20
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Müllerian adenosarcoma of the uterus with sarcomatous overgrowth following tamoxifen treatment for breast cancer.
  • Müllerian adenosarcoma with sarcomatous overgrowth presented by a 52-year-old female patient after adjuvant tamoxifen treatment for breast carcinoma is described.
  • The diagnosis was made on histological basis after curettage and complementary total hysterectomy with bilateral salpingo-oophorectomy.
  • [MeSH-major] Adenosarcoma / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10881074.001).
  • [ISSN] 0041-8781
  • [Journal-full-title] Revista do Hospital das Clínicas
  • [ISO-abbreviation] Rev Hosp Clin Fac Med Sao Paulo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] BRAZIL
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


3. Yoney A, Eren B, Eskici S, Salman A, Unsal M: Retrospective analysis of 105 cases with uterine sarcoma. Bull Cancer; 2008 Mar;95(3):E10-7
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of 105 cases with uterine sarcoma.
  • To evaluate the role of adjuvant therapy in survival and to identify important prognostic factors in uterine sarcoma.
  • One hundred five patients with uterine sarcoma have been retrospectively researched to evaluate the results in this tumor group.
  • 38.1% of the patients had Radiotherapy, 18.1% had chemotherapy and 12.4% had chemoradiotherapy in addition to surgery.
  • In our series, univariate analysis for overall survival demonstrated statistical significance for radical surgery, grade, stage, age, menopausal status and presence of RT in treatment modality, but; histology, number of mitosis, tumor size demonstrated no significance.
  • Our data favors treatment for uterine sarcoma with radical surgery plus radiotherapy alone over 54 Gy or with chemotherapy.
  • [MeSH-major] Leiomyosarcoma. Mixed Tumor, Mullerian. Sarcoma, Endometrial Stromal. Uterine Neoplasms
  • [MeSH-minor] Adenosarcoma / mortality. Adenosarcoma / pathology. Adenosarcoma / secondary. Adenosarcoma / therapy. Adult. Aged. Aged, 80 and over. Analysis of Variance. Bone Neoplasms / secondary. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18390406.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] France
  •  go-up   go-down


Advertisement
4. Hassini A, Khemiri B, Sfar E, Chelly D, Chennoufi MB, Chelly H: [Uterine sarcomas: clinical and therapeutic aspects (10 cases)]. J Gynecol Obstet Biol Reprod (Paris); 2006 Jun;35(4):348-55
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Uterine sarcomas: clinical and therapeutic aspects (10 cases)].
  • [Transliterated title] Sarcomes utérins: aspects cliniques et thérapeutiques. A propos de 10 cas.
  • PURPOSE: Uterine sarcomas are rare tumours characterized by clinical and histopathological diversity and poor prognosis.
  • We analyzed diagnostic, prognostic and therapeutic difficulties encountered with these tumors by insisting on the importance of early diagnosis.
  • PATIENTS AND METHODS: From 1997 to 2004 ten patients with uterine sarcoma who underwent surgery in the obstetrics and gynecology unit at the Tunis maternity center were included in this retrospective study.
  • The tumors were classified at the time of diagnosis using the FIGO staging system.
  • The histological diagnosis was based on the WHO classification.
  • RESULTS: There were 5 cases of leiomyosarcoma, 2 cases of carcinosarcoma, 2 cases of endometrial stromal sarcoma and 1 adenosarcoma.
  • The diagnosis of uterine sarcoma was strongly suspected and proved before the initial operation in 20% of cases and during this operation in 60% of cases.
  • Diagnosis was only established at the histological exam in two cases.
  • Radiation therapy was performed in four.
  • Chemotherapy was delivered in two patients.
  • CONCLUSION: Early preoperative or intra-operative diagnosis is essential while awaiting for more effective chemotherapy protocols or therapeutic strategies.
  • [MeSH-major] Hysterectomy. Ovariectomy. Sarcoma / surgery. Uterine Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16940904.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 40
  •  go-up   go-down


5. Ozmen B, Uzum N, Unlu C, Ortac F, Ataoglu O: Surgical conservation of both ovaries in an adolescent with uterine müllerian adenosarcoma: a case report. J Minim Invasive Gynecol; 2007 May-Jun;14(3):375-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical conservation of both ovaries in an adolescent with uterine müllerian adenosarcoma: a case report.
  • However, data on conservation of ovaries in uterine müllerian adenosarcoma are limited due to its very rare incidence in reproductive-aged females.
  • Conservation of both ovaries along with adjuvant chemotherapy was performed in a 14-year-old girl with uterine adenosarcoma.
  • Therefore, surgical conservation of ovaries might be a solution for fertility sparing in uterine müllerian adenosarcoma.
  • [MeSH-major] Adenosarcoma / surgery. Mixed Tumor, Mullerian / surgery. Uterine Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17478375.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Fait T, Zivny J, Freitag P, Kuzel D: Adenosarcoma of the uterine body in a 19-year-old woman--three year survival: case report. Eur J Gynaecol Oncol; 2001;22(1):61-3
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosarcoma of the uterine body in a 19-year-old woman--three year survival: case report.
  • BACKGROUND: Uterine adenosarcoma is a rarely by occurring tumor.
  • The average age of patients with a diagnosis of uterine adenosarcoma is about 70 years.
  • CASE: We present a case of a 19-year-old woman with a rarely occurring uterine adenosarcoma manifesting itself by irregular bleeding and producing fragile polypous matter which was spreading into the vagina.
  • The final diagnosis was made only by repeated biopsies.
  • Teleradiotherapy was applied from 4 fields in 25 fractions to a total exposure of 50 Gy.
  • It was followed by six cycles of chemotherapy containing 50 mg/m2 doxorubicin and 5 g/m2 ifosfamid administered in 21-day dose intervals.
  • CONCLUSION: This case should demonstrate the difficulty of making the right diagnosis.
  • Since the end of therapy the patient has been regularly seen in our onco-gynecologic department.
  • Now, 40 months after the end of chemotherapy and 46 months after making the diagnosis, there are no signs of relapse.
  • [MeSH-major] Adenosarcoma / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Follow-Up Studies. Humans. Hysterectomy. Uterus / pathology. Vagina / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11321498.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


7. Arici DS, Aker H, Yildiz E, Tasyurt A: Mullerian adenosarcoma of the uterus associated with tamoxifen therapy. Arch Gynecol Obstet; 2000 Sep;264(2):105-7
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mullerian adenosarcoma of the uterus associated with tamoxifen therapy.
  • Mullerian adenosarcoma of the uterus is a biphasic tumor exhibiting benign epithelial and malignant stromal component.
  • This tumor may occasionally be associated with tamoxifen therapy which is used as an adjuvant drug for breast carcinoma.
  • Reviewing the literature, we found only 12 adenosarcoma cases associated with tamoxifen therapy Thus, the clinical and pathological findings in a 58 years old postmenopausal woman who developed uterine adenosarcoma, following low dose tamoxifen therapy after 8 years, was discussed in this report.
  • [MeSH-major] Adenosarcoma / chemically induced. Estrogen Antagonists / adverse effects. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced
  • [MeSH-minor] Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / therapy. Female. Humans. Middle Aged. Postmenopause

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11045336.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


8. Krivak TC, Seidman JD, McBroom JW, MacKoul PJ, Aye LM, Rose GS: Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival. Gynecol Oncol; 2001 Oct;83(1):89-94
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
  • OBJECTIVE: Uterine adenosarcoma with sarcomatous overgrowth (ASSO) is a rare variant of uterine sarcoma first described in 1989.
  • This clinicopathologic study was undertaken to compare the treatment and survival of uterine adenosarcoma with sarcomatous overgrowth to that of uterine carcinosarcomas.
  • METHODS: A review of uterine sarcomas diagnosed at Washington Hospital Center from January 1988 to December 1998 was performed.
  • Records were reviewed for demographic data, surgical staging, primary and adjuvant therapy, metastatic site, disease recurrence, and survival.
  • All pathology was reviewed and diagnosis confirmed.
  • Statistical analysis included chi(2) test and Student's t test.
  • Kaplan-Meier survival curves were plotted to estimate the median and 5-year survival times.
  • The log-rank test was used to compare survival times.
  • RESULTS: Sixty patients were diagnosed with uterine sarcoma at Washington Hospital Center.
  • Of these, 33 (55%) were uterine carcinosarcomas, 11 (18%) ASSOs, 6 (10%) adenosarcomas, and 10 (17%) leiomyosarcomas.
  • Of the patients diagnosed with uterine ASSO, 3 (27%) were stage I, 3 (27%) stage II, 1 (9%) stage III, and 4 (36%) stage IV.
  • All 11 patients with uterine ASSO underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy and tumor debulking.
  • Postoperative adjuvant therapy included chemotherapy (n = 4), radiation (n = 4), combination radiation and chemotherapy (n = 1), and no adjuvant therapy (n = 2).
  • The overall median survival time of patients with uterine ASSO was 13 months.
  • Twenty-seven of the twenty-nine patients diagnosed with carcinosarcoma underwent surgical therapy to include total abdominal hysterectomy, bilateral salpingo-oophorectomy, staging and tumor debulking.
  • Two patients died prior to treatment.
  • Postoperative adjuvant therapy included chemotherapy (n = 9), radiation (n = 13), combination (n = 1), and no further therapy (n = 4).
  • Twenty of the twenty-nine patients are dead of disease; there were nine surviving patients at the time of this report (stage I-5, stage II-3, stage III-1).
  • Comparison of the Kaplan-Meier survival curves using the log-rank test suggests a worse prognosis for uterine ASSO.
  • CONCLUSIONS: Patients diagnosed with uterine ASSO have a poor prognosis similar to that of carcinosarcoma.
  • Additional therapy in the form of radiation, chemotherapy, or both has been reported; however, the superiority of one modality could not be determined from our data.
  • [MeSH-major] Adenosarcoma / therapy. Carcinosarcoma / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Ovariectomy. Radiotherapy, Adjuvant. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11585418.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. del Carmen MG, Lovett D, Goodman A: A case of Müllerian adenosarcoma of the uterus treated with liposomal doxorubicin. Gynecol Oncol; 2003 Mar;88(3):456-8
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of Müllerian adenosarcoma of the uterus treated with liposomal doxorubicin.
  • OBJECTIVE: We report on a case of uterine a denosarcoma responsive to treatment with liposomal doxorubicin (Doxil).
  • RESULTS: A 69-year-old woman presented to our institution with dehydration and failure to thrive, and recurrent uterine adenosarcoma, 9 months after initial diagnosis.
  • She had undergone total abdominal hysterectomy and bilateral salpingo-oophorectomy at the time of diagnosis, followed by two cycles of Ifosfamide and treatment with megestrol acetate.
  • She underwent treatment with six cycles of liposomal doxorubicin with a marked response.
  • Given the development of Grade II hand-foot syndrome, liposomal doxorubicin was stopped and two cycles of carboplatin/paclitaxel chemotherapy were administered.
  • The patient developed disease recurrence after a 7-month disease-free interval and 2 years after initial diagnosis.
  • Following another two cycles of liposomal doxorubicin, the patient underwent another cytoreductive procedure for recurrent disease.
  • Two months later, the patient expired, 29 months after diagnosis and 20 months after initial treatment with liposomal doxorubicin chemotherapy.
  • CONCLUSIONS: Liposomal doxorubicin appears to be active in the treatment of recurrent uterine adenosarcoma.
  • [MeSH-major] Adenosarcoma / drug therapy. Doxorubicin / therapeutic use. Mixed Tumor, Mullerian / drug therapy. Uterine Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12648604.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin
  •  go-up   go-down


10. Shi Y, Liu Z, Peng Z, Liu H, Yang K, Yao X: The diagnosis and treatment of Mullerian adenosarcoma of the uterus. Aust N Z J Obstet Gynaecol; 2008 Dec;48(6):596-600
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnosis and treatment of Mullerian adenosarcoma of the uterus.
  • BACKGROUND: Adenosarcoma of the uterus is one of the rare types of gynaecological malignant tumours.
  • AIM: To improve the level of diagnosis and treatment of Mullerian adenosarcoma of the uterus.
  • METHODS: The medical data of nine patients with Mullerian adenosarcoma of the uterus who were treated from May 1995 to March 2006 in our hospital were analysed retrospectively.
  • The analysis focused on clinicopathological features, treatment and prognosis.
  • RESULTS: Patients typically presented with abnormal uterine bleeding, pain in the lower abdomen, enlargement of the uterus, a mass in the uterine cavity and/or a cervical neoplasm.
  • The primary diagnostic rate was 33.3% and the average interval from symptom onset to final diagnosis was 13 months and eight weeks for pre- and postmenopausal patients, respectively.
  • CONCLUSIONS: The most common symptom of adenosarcoma of the uterus is abnormal uterine bleeding.
  • Surgery is the primary treatment, and chemotherapy may be somewhat beneficial.
  • [MeSH-major] Adenosarcoma / diagnosis. Mixed Tumor, Mullerian / diagnosis. Neoplasms, Germ Cell and Embryonal / diagnosis. Uterine Cervical Neoplasms / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adult. Age Factors. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19133051.001).
  • [ISSN] 1479-828X
  • [Journal-full-title] The Australian & New Zealand journal of obstetrics & gynaecology
  • [ISO-abbreviation] Aust N Z J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


11. Soh E, Eleti A, Jimenez-Linan M, Arends MJ, Latimer J, Sala E: Magnetic resonance imaging findings of tamoxifen-associated uterine Müllerian adenosarcoma: a case report. Acta Radiol; 2008 Sep;49(7):848-51
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging findings of tamoxifen-associated uterine Müllerian adenosarcoma: a case report.
  • Müllerian adenosarcoma of the uterus is a rare biphasic tumor, which was first described in 1974.
  • Recent studies have suggested an association with tamoxifen therapy, but there have been few reports with detailed imaging findings.
  • We present a case with magnetic resonance imaging (MRI) findings of this rare tumor in a woman who received long-term tamoxifen therapy for breast cancer.
  • [MeSH-major] Adenosarcoma / chemically induced. Adenosarcoma / diagnosis. Antineoplastic Agents, Hormonal / adverse effects. Magnetic Resonance Imaging / methods. Mullerian Ducts / pathology. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Breast Neoplasms / drug therapy. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19143068.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


12. Han XY, Xiang Y, Guo LN, Sheng K, Wan XR, Huang HF, Pan LY: [Mullerian adenosarcoma of the uterus: A clinicopathologic analysis of 9 cases]. Zhonghua Zhong Liu Za Zhi; 2010 Jan;32(1):44-7
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mullerian adenosarcoma of the uterus: A clinicopathologic analysis of 9 cases].
  • OBJECTIVE: To investigate the clinicopathologic features, diagnosis, treatment and prognosis of uterine mullerian adenosarcoma.
  • METHODS: The clinicopathological data of 9 cases of uterine mullerian adenosarcoma in PUMC hospital from January 2003 to February 2009 were retrospectively analyzed.
  • RESULTS: There were 6 uterine endometrial adenosarcomas and 3 cervical adenosarcomas.
  • Physical examination showed cervical/vaginal mass, enlarged uterus or pelvic mass.
  • The adenosarcoma was characterized by benign or atypical-appearing neoplastic glands within a sarcomatous stroma.
  • All patients received surgical treatment and seven had postoperative chemotherapy, radiotherapy or hormone therapy.
  • During the follow-up, 2 cases of uterine endometrial adenosarcoma recurred.
  • The other one recurred 2 years after local excision of the tumor in the uterine cavity and she remained healthy since hysterectomy.
  • CONCLUSION: Uterine mullerian adenosarcoma is a rare tumor without specific clinical symptoms and signs.
  • The diagnosis depends on pathomorphologic examination.
  • Surgical excision is the main treatment strategy with a good prognosis in the early stage disease with complete removal of tumors.
  • The prognosis is poor in advanced adenosarcoma with sarcomatous overgrowth.
  • [MeSH-major] Endometrial Neoplasms / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenosarcoma / drug therapy. Adenosarcoma / pathology. Adenosarcoma / surgery. Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Ifosfamide / therapeutic use. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Uterine Neoplasms / drug therapy. Uterine Neoplasms / pathology. Uterine Neoplasms / surgery. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20211067.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; Adenosarcoma of the uterus; ICE protocol 1
  •  go-up   go-down


13. Guidozzi F, Smith T, Koller AB, Reinecke L: Management of uterine Müllerian adenosarcoma with extrauterine metastatic deposits. Gynecol Oncol; 2000 Jun;77(3):464-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of uterine Müllerian adenosarcoma with extrauterine metastatic deposits.
  • OBJECTIVE: The aim of this study was to provide the management and outcome of three patients who presented with uterine Müllerian adenosarcoma associated with extrauterine metastases.
  • RESULTS: In two patients the preoperative diagnosis and extent of their disease were known while in the third patient the diagnosis was only made postoperatively.
  • All patients had a type II radical abdominal hysterectomy, bilateral salpingo-oophorectomy, and omentectomy.
  • Two patients were given three cycles of neoadjuvant chemotherapy and pelvic irradiation over 12 weeks.
  • Both of these patients had their diagnosis made preoperatively and the chemotherapy consisted of 240 mg/m(2) carboplatin and 80 mg/m(2) farmorubicin per cycle.
  • The pelvic irradiation consisted of daily fractions of 1.8-Gy irradiation to a total of 45 Gy over the first 6 weeks.
  • CONCLUSION: Radical surgery, chemotherapy, and irradiation provide a management option with seemingly favorable outcome for patients with uterine Müllerian adenosarcoma associated with extrauterine metastases.
  • [MeSH-major] Adenosarcoma / therapy. Mixed Tumor, Mullerian / therapy. Omentum. Peritoneal Neoplasms / secondary. Uterine Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Middle Aged. Neoadjuvant Therapy. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • [ErratumIn] Gynecol Oncol 2001 Sep;82(3):591
  • (PMID = 10831361.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


14. Farhat F, Fakhruddine N: A case of synchronous relapse of breast cancer and uterine müllerian adenosarcoma post tamoxifen in a premenopausal woman. Eur J Gynaecol Oncol; 2008;29(1):95-7
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of synchronous relapse of breast cancer and uterine müllerian adenosarcoma post tamoxifen in a premenopausal woman.
  • PURPOSE & METHODS: We report a case of a 42-year-old multigravida, premenopausal woman with breast carcinoma, who presented after four years of use of adjuvant tamoxifen with synchronous liver, bone, and lung metastasis of breast cancer with müllerian adenosarcoma.
  • RESULTS: Immunohistochemical stains on the uterine tumor for estrogen and progesterone receptors showed positivity for both epithelial and stromal cells, actin, and desmin while the proliferative index (MIB-1) showed positivity for stromal cells only.
  • The patient underwent a hysterectomy followed by palliative chemotherapy.
  • CONCLUSION: Our case is the only one reported in the literature with synchronous relapse of breast adenocarcinoma and a Müllerian adenosarcoma.
  • [MeSH-major] Adenosarcoma / pathology. Breast Neoplasms / drug therapy. Mixed Tumor, Mullerian / pathology. Neoplasm Recurrence, Local / complications. Tamoxifen / adverse effects. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Metastasis. Premenopause. Treatment Failure

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18386476.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 12
  •  go-up   go-down


15. Murugasu A, Miller J, Proietto A, Millar E: Extragenital mullerian adenosarcoma with sarcomatous overgrowth arising in an endometriotic cyst in the pouch of Douglas. Int J Gynecol Cancer; 2003 May-Jun;13(3):371-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extragenital mullerian adenosarcoma with sarcomatous overgrowth arising in an endometriotic cyst in the pouch of Douglas.
  • Mullerian adenosarcoma is a neoplasm composed of benign mullerian epithelium and a sarcomatous stroma.
  • Rare cases of extragenital adenosarcoma have been reported.
  • We present the case of a 23-year-old female who presented with an extragenital adenosarcoma arising in an endometriotic cyst in the pouch of Douglas.
  • The patient was treated with local excision, chemotherapy and radiotherapy.
  • The literature on extragenital adenosarcoma is reviewed.
  • These tumors are clinically more aggressive than their uterine counterparts.
  • Surgical excision is the initial treatment modality for these patients.
  • Little information is available regarding the efficacy of adjuvant chemotherapy or radiotherapy.
  • [MeSH-major] Adenosarcoma / pathology. Douglas' Pouch. Mixed Tumor, Mullerian / pathology. Peritoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12801272.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  •  go-up   go-down


16. Johnson SR, Ettinger B, Macer JL, Ensrud KE, Quan J, Grady D: Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. Obstet Gynecol; 2005 Apr;105(4):779-87
Hazardous Substances Data Bank. ESTRADIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol.
  • OBJECTIVE: To investigate uterine effects of unopposed ultralow-dose transdermal estradiol administered to postmenopausal women for 2 years.
  • METHODS: Postmenopausal women (n = 417), aged 60-80 years, with a uterus and with bone mineral density that was normal for age (z score >or=-2.0) were randomly assigned to receive unopposed transdermal estradiol (14 microg per day) or identical placebo patch.
  • In the estradiol group, focal atypical endometrial hyperplasia developed in 1 woman, and adenosarcoma of the uterus developed in 1 woman.
  • CONCLUSION: During 2 years of treatment with ultralow-dose unopposed estradiol, treatment and placebo groups had similar rates of endometrial hyperplasia, endometrial proliferation, and vaginal bleeding.
  • This therapy apparently causes little or no endometrial stimulation.
  • [MeSH-major] Estradiol / administration & dosage. Hot Flashes / prevention & control. Uterus / drug effects. Vagina / drug effects
  • [MeSH-minor] Administration, Cutaneous. Aged. Aged, 80 and over. Drug Administration Schedule. Female. Humans. Middle Aged. Postmenopause. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15802405.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 4TI98Z838E / Estradiol
  •  go-up   go-down


17. Ramos P, Ruiz A, Carabias E, Piñero I, Garzon A, Alvarez I: Müllerian adenosarcoma of the cervix with heterologous elements: report of a case and review of the literature. Gynecol Oncol; 2002 Jan;84(1):161-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Müllerian adenosarcoma of the cervix with heterologous elements: report of a case and review of the literature.
  • BACKGROUND: Müllerian adenosarcoma (MA) is a rare neoplasm composed of benign epithelial and malignant stromal components.
  • We describe another case of MA of the uterine cervix with heterologous elements and review the clinical and pathological features of these tumors.
  • The epithelial elements were benign endocervical type glands, and the mesenchymal were sarcomatous, containing minor foci of cartilage.
  • A diagnosis of endocervical heterologous adenosarcoma was reached, and a total hysterectomy and bilateral salpingo-oophorectomy were performed.
  • The patient is alive 2 years after the surgical procedure.
  • Neither chemotherapy nor other adjuvant therapies have been administered, and she is clinically free of disease at the moment.
  • [MeSH-major] Adenosarcoma / pathology. Mixed Tumor, Mullerian / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11748995.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


18. Park HM, Park MH, Kim YJ, Chun SH, Ahn JJ, Kim CI, Sung SH, Han WS, Kim SC: Mullerian adenosarcoma with sarcomatous overgrowth of the cervix presenting as cervical polyp: a case report and review of the literature. Int J Gynecol Cancer; 2004 Sep-Oct;14(5):1024-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mullerian adenosarcoma with sarcomatous overgrowth of the cervix presenting as cervical polyp: a case report and review of the literature.
  • An aggressive variant of adenosarcoma, mullerian adenosarcoma with sarcomatous overgrowth (MASO) in the cervix is extremely rare.
  • In this report, we describe a case of MASO of the uterine cervix and review the clinical and pathological features of these tumors.
  • The patient has been followed-up and neither chemotherapy nor other adjuvant therapies have been administered.
  • It is extremely rare that MASO of the uterine cervix is presented in premenopausal woman.
  • Gynecologists and pathologists should be aware of the difficulties associated with a delay in the diagnosis of MASO when the tumor is present as a benign looking cervical polyp.
  • [MeSH-major] Adenosarcoma / pathology. Adenosarcoma / surgery. Polyps / pathology. Polyps / surgery. Uterine Cervical Diseases / pathology. Uterine Cervical Diseases / surgery. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Diagnosis, Differential. Disease-Free Survival. Fallopian Tubes / surgery. Female. Humans. Hysterectomy. Ovariectomy


19. Lee SJ, Bae JH, Kim DC, Park JS, Namkoong SE: Oral progesterone treatment in a young woman with müllerian adenosarcoma whose ovary was preserved: a case report. Int J Gynecol Cancer; 2010 Oct;20(7):1222-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral progesterone treatment in a young woman with müllerian adenosarcoma whose ovary was preserved: a case report.
  • Müllerian adenosarcoma is a rare biphasic tumor in young women.
  • A 35-year-old woman had a diagnosis of adenosarcoma on hysteroscopic resection, which was estrogen and progesterone receptor positive.
  • She underwent total hysterectomy with ovary conservation and has received oral medroxyprogesterone acetate treatment.
  • Oral medroxyprogesterone acetate therapy can be used effectively in young women with müllerian adenosarcoma whose ovaries are preserved.
  • [MeSH-major] Adenosarcoma / drug therapy. Antineoplastic Agents, Hormonal / administration & dosage. Medroxyprogesterone Acetate / administration & dosage. Mixed Tumor, Mullerian / drug therapy. Ovary / drug effects. Pregnancy Complications, Neoplastic / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Female. Humans. Hysterectomy. Hysteroscopy. Pregnancy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21495235.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


20. Fleming NA, Hopkins L, de Nanassy J, Senterman M, Black AY: Mullerian adenosarcoma of the cervix in a 10-year-old girl: case report and review of the literature. J Pediatr Adolesc Gynecol; 2009 Aug;22(4):e45-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mullerian adenosarcoma of the cervix in a 10-year-old girl: case report and review of the literature.
  • Müllerian adenosarcoma is a rare neoplasm usually found in postmenopausal women.
  • We present a case of a 10-year-old girl who was diagnosed with müllerian adenosarcoma arising from the endocervix, the youngest female ever reported.
  • The final pathology revealed müllerian adenosarcoma, favoring an endocervical origin.
  • Hysteroscopic inspection of the uterine cavity did not find any abnormalities.
  • Pathology confirmed a diagnosis of müllerian adenosarcoma originating from the endocervix.
  • Uterine curettings were negative for malignancy.
  • After a thorough evaluation of the available literature, review with the Regional Tumor Board and extensive discussions with the family, a decision was made to perform a radical hysterectomy, bilateral salpingectomy, bilateral pelvic lymph node dissection, upper vaginectomy and preservation of ovaries.
  • The procedure was uncomplicated.
  • CONCLUSION: Müllerian adenosarcoma of the endocervix is a very rare pediatric tumor.
  • Due to the rarity of this tumor in this age group, optimal therapy is uncertain.
  • Chemotherapy and radiation have not been used in the absence of extensive pelvic and/or residual disease.
  • If recurrence occurs, it tends to be local and following prior conservative treatments such as cone biopsy or trachelectomy.
  • [MeSH-major] Adenosarcoma / pathology. Uterine Cervical Neoplasms / pathology


21. Gallardo A, Prat J: Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma. Am J Surg Pathol; 2009 Feb;33(2):278-88
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma.
  • Mullerian adenosarcomas are rare mixed tumors of low malignant potential that occur mainly in the uterus and also in extrauterine locations.
  • Thirty-seven tumors were of the uterine corpus, 11 of the cervix, 4 of the ovary, and 1 each of the fallopian tube, vagina, and Douglas peritoneum.
  • Treatment was known in 50 patients: 10 had polypectomy, 1 cone biopsy, and 39 hysterectomy, which was accompanied by bilateral salpingo-oophorectomy in 24 and lymphadenectomy in 4.
  • Five patients had radiotherapy and 2 of them had chemotherapy.
  • Of 30 tumors of the uterine corpus, 17 were stage IA, 11 stage IB, 1 stage IC, and 1 stage IIIC.
  • The tumor of the fallopian tube was stage IC, and the tumors of the vagina and recto-uterine pouch were confined to their site of origin.
  • Most uterine tumors were polypoid masses ranging from 1 to 20 cm (mean: 6.5 cm).
  • Fourteen of 30 uterine tumors (47%) had myometrial invasion that was minimal in 5, involved one-third of the myometrial thickness in 7, and more than 50% in 2.
  • Six developed metastases and 5 of them died of tumor.
  • Four had adenosarcomas with sarcomatous overgrowth; however, the other 2 patients had typical low-grade adenosarcomas of the uterine corpus and cervix, respectively, exhibiting only mild nuclear atypia of the stromal component and </=2 mitotic figures/10 high power fields.
  • [MeSH-major] Adenofibroma / pathology. Adenosarcoma / pathology. Genital Neoplasms, Female / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Mitotic Index. Neoplasm Staging. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18941402.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


22. Arenas M, Rovirosa A, Hernández V, Ordi J, Jorcano S, Mellado B, Biete A: Uterine sarcomas in breast cancer patients treated with tamoxifen. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):861-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine sarcomas in breast cancer patients treated with tamoxifen.
  • Tamoxifen (TMX) has been related with the development of uterine sarcomas.
  • Here we present three new cases of uterine sarcomas in patients with breast cancer treated with TMX and we comment on the outcome of the cases described in the literature.
  • In the past 25 years, 60 uterine sarcomas have been diagnosed and treated in Hospital Clínic.
  • Uterine sarcoma appeared 5, 5, and 7 years, respectively, after the start of TMX treatment, and all of them had stage I (FIGO) disease.
  • Two patients had a carcinosarcoma and one patient had an adenosarcoma.
  • After treatment, the disease progressed in two patients and the third patient is alive having a follow-up of 42 months.
  • The low incidence of uterine sarcomas makes it difficult to establish a relationship with TMX.
  • Nevertheless, looking at the literature data, 20 mg/day of TMX over 1 year could be enough to develop uterine sarcoma; the sarcoma appears mainly during the first 8 years and seem to behave more aggressively.
  • Although only 65 cases have been reported in the past 14 years, a strict follow-up is necessary in patients with breast cancer receiving TMX therapy.
  • [MeSH-major] Adenosarcoma / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Carcinosarcoma / chemically induced. Neoplasms, Second Primary / chemically induced. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681774.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


23. Köhler G: [Uterine sarcoma treatment]. Pathologe; 2009 Jul;30(4):304-12
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Uterine sarcoma treatment].
  • There are many common features between uterine sarcomas - leiomyosarcoma, endometrial stromal sarcoma, undifferentiated endometrial sarcoma and adenosarcoma -with regards to course, therapy and follow-up, such as post-menopausal bleeding or additional premenopausal bleeding, as well as rapid growth.
  • There is a new staging system according to FIGO and new therapy recommendations according to NCCN.
  • Prior to therapy, imaging staging of the pelvis, abdomen and chest should be carried out due to the frequency with which metastases are found at the time of diagnosis.
  • In the case of disease spread in uterine sarcomas and malignant mixed tumors, good supportive therapy is a possible therapy option instead of chemo- or radiotherapy.
  • The approach - observation, surgery, lymphonodectomy, mono- or polychemotherapy, radiotherapy, hormone therapy - is chosen according to the extent of spread and the resection status.
  • Neoadjuvant therapies are not as yet established.
  • [MeSH-major] Sarcoma / drug therapy. Sarcoma / radiotherapy. Uterine Neoplasms / drug therapy. Uterine Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1994 Jan;52(1):74-9 [8307505.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):460-9 [12798712.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):820-30 [18189292.001]
  • [Cites] Gynecol Oncol. 2001 Oct;83(1):89-94 [11585418.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):644-7 [14766260.001]
  • [Cites] Gynecol Oncol. 1993 Jul;50(1):105-9 [8349151.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1240-5 [3897471.001]
  • [Cites] Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1084-9 [18179547.001]
  • [Cites] Curr Opin Oncol. 2007 Jul;19(4):347-52 [17545798.001]
  • [Cites] Gynecol Oncol. 2009 Mar;112(3):563-7 [19135708.001]
  • [Cites] Oncol Rep. 1998 Jul-Aug;5(4):939-44 [9625851.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Feb;65(2):129-42 [17706430.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):226-9 [8751554.001]
  • [Cites] Ann Surg. 1999 May;229(5):602-10; discussion 610-2 [10235518.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):500-5 [10749609.001]
  • [Cites] Gynecol Oncol. 2008 Jul;110(1):43-8 [18445505.001]
  • [Cites] Int J Gynecol Cancer. 2007 Sep-Oct;17(5):957-63 [17359294.001]
  • [Cites] Gynecol Oncol. 2008 Oct;111(1):74-81 [18657852.001]
  • [Cites] Cancer. 1993 Feb 15;71(4 Suppl):1702-9 [8381710.001]
  • [Cites] Cancer. 1983 Aug 15;52(4):626-32 [6344983.001]
  • [Cites] Int J Gynecol Pathol. 1992;11(2):75-88 [1316323.001]
  • [Cites] Gynecol Oncol. 1990 Jan;36(1):113-8 [2295442.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2009 May;144(1):80-4 [19269732.001]
  • [Cites] Eur J Gynaecol Oncol. 2006;27(2):150-2 [16620058.001]
  • [Cites] Gynecol Obstet Fertil. 2003 Feb;31(2):147-50 [12718990.001]
  • [Cites] Gynecol Oncol. 2007 Jul;106(1):82-8 [17434579.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):170-6 [12821359.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3144-50 [17634494.001]
  • [Cites] Am J Obstet Gynecol. 1992 Feb;166(2):556-9 [1536229.001]
  • [Cites] Obstet Gynecol. 1996 May;87(5 Pt 1):747-50 [8677079.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):492-6 [17762577.001]
  • [Cites] Br J Cancer. 1995 Aug;72(2):469-75 [7640234.001]
  • [Cites] Gynecol Oncol. 2008 Jun;109(3):329-34 [18534250.001]
  • [Cites] Br J Cancer. 2007 Nov 5;97(9):1194-9 [17895898.001]
  • [Cites] Obstet Gynecol. 2008 Jul;112(1):64-70 [18591309.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1998 Feb;76(2):237-40 [9481582.001]
  • [Cites] Mod Pathol. 2004 Jan;17(1):104-8 [14631363.001]
  • [Cites] Gynecol Oncol. 1996 Jul;62(1):25-32 [8690287.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):36-42 [15992918.001]
  • [Cites] Int J Gynecol Cancer. 2005 Jan-Feb;15(1):132-9 [15670308.001]
  • [Cites] Hum Pathol. 1990 Apr;21(4):363-81 [2156771.001]
  • [Cites] Eur J Cancer. 2008 Apr;44(6):808-18 [18378136.001]
  • [Cites] Eur J Gynaecol Oncol. 2008;29(2):129-34 [18459545.001]
  • [Cites] Gynecol Oncol. 2006 Jun;101(3):464-9 [16368128.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1358-63 [16803530.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):254-9 [8751558.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2008 Aug;20(6):470-8 [18572394.001]
  • [Cites] Oncology. 2006;71(5-6):333-40 [17690557.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):648-52 [14766261.001]
  • [Cites] Am J Surg Pathol. 2008 Jul;32(7):1013-21 [18469708.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):256-60 [17292949.001]
  • [Cites] Obstet Gynecol. 2008 Nov;112(5):1102-8 [18978112.001]
  • [Cites] Obstet Gynecol. 2005 Dec;106(6):1304-8 [16319256.001]
  • [Cites] Br J Cancer. 2008 Oct 21;99(8):1210-5 [18813312.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1366-73 [14630275.001]
  • [Cites] Ann Surg Oncol. 2005 Jun;12(6):459-66 [15886903.001]
  • [Cites] Eur J Cancer. 1997 May;33(6):907-11 [9291814.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):243-5 [16054205.001]
  • [Cites] Br J Cancer. 2000 Mar;82(5):1030-4 [10737385.001]
  • [Cites] Int J Gynecol Cancer. 2007 May-Jun;17(3):724-8 [17300682.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1228-38 [18580489.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):204-8 [15047237.001]
  • [Cites] Am J Obstet Gynecol. 2008 Nov;199(5):536.e1-8 [18511017.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):402-6 [15661228.001]
  • [Cites] J Clin Oncol. 2009 Apr 20;27(12):2066-72 [19255317.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):540-7; discussion 547-8 [11573047.001]
  • [Cites] Gynecol Oncol. 2007 Dec;107(3):518-25 [17910981.001]
  • [Cites] Gynecol Oncol. 2007 Jan;104(1):260-3 [17083970.001]
  • [Cites] Gynecol Oncol. 1992 May;45(2):202-5 [1592288.001]
  • [Cites] Gynecol Oncol. 2007 Jun;105(3):630-4 [17320937.001]
  • [Cites] Int J Gynecol Pathol. 1999 Jan;18(1):20-8 [9891238.001]
  • [Cites] J Obstet Gynaecol Can. 2008 Jun;30(6):500-4 [18611301.001]
  • [Cites] Histopathology. 2009 Feb;54(3):355-64 [19236512.001]
  • [Cites] Int J Gynecol Cancer. 2009 Feb;19(2):253-6 [19396004.001]
  • [Cites] Int J Gynecol Cancer. 2009 Feb;19(2):257-60 [19396005.001]
  • [Cites] Int J Gynecol Cancer. 2004 Nov-Dec;14(6):1118-21 [15571618.001]
  • [Cites] Gynecol Oncol. 2002 Dec;87(3):287-94 [12468327.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):209-12 [14529683.001]
  • [Cites] Cancer. 1985 Apr 15;55(8):1648-53 [3884128.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):306-11 [18061249.001]
  • [Cites] Am J Surg Pathol. 2009 Feb;33(2):278-88 [18941402.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • (PMID = 19517111.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


24. Martin-Loeches M, Rius J, Orti RM: Uterine sarcoma associated with tamoxifen use: case report. Eur J Gynaecol Oncol; 2003;24(2):202-3
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine sarcoma associated with tamoxifen use: case report.
  • A case of müllerian adenosarcoma with sarcomatous overgrowth in a postmenopausal 66-year-old female patient after adjuvant tamoxifen treatment for breast carcinoma is described.
  • The diagnosis was based on the histological findings after curettage and complementary total hysterectomy with bilateral salpingo-oophorectomy.
  • [MeSH-major] Adenosarcoma / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Carcinoma, Ductal, Breast / drug therapy. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced
  • [MeSH-minor] Aged. Breast Neoplasms / drug therapy. Female. Humans. Postmenopause

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12701980.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


25. Ioffe YJ, Li AJ, Walsh CS, Karlan BY, Leuchter R, Forscher C, Cass I: Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles. Gynecol Oncol; 2009 Dec;115(3):466-71
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles.
  • OBJECTIVES.: The utility of hormone therapy in the management of uterine sarcomas is poorly defined.
  • We hypothesize that estrogen receptor (ER) expression is common in uterine sarcomas, and carries prognostic significance.
  • Further, we hypothesize that ER-positive uterine sarcomas respond to hormone therapy.
  • METHODS.: We retrospectively reviewed charts of patients with uterine sarcomas.
  • Four patients received hormonal treatment in the adjuvant setting and remained in remission (range of follow up: 18-68 months).
  • Eighteen patients received hormone therapy in the setting of recurrent or progressive disease: fourteen (78%) demonstrated stable disease or complete or partial response (range of follow up: 6-124 months).
  • CONCLUSIONS.: ER expression is common and is associated with improved overall survival in uterine sarcomas.
  • Hormone therapy should be considered in patients with primary and recurrent ER-positive uterine sarcomas.
  • [MeSH-major] Receptors, Estrogen / biosynthesis. Sarcoma / metabolism. Uterine Neoplasms / metabolism
  • [MeSH-minor] Adenosarcoma / drug therapy. Adenosarcoma / metabolism. Adenosarcoma / pathology. Antineoplastic Agents, Hormonal / pharmacology. Aromatase Inhibitors / pharmacology. Carcinosarcoma / drug therapy. Carcinosarcoma / metabolism. Carcinosarcoma / pathology. Female. Humans. Retrospective Studies. Sarcoma, Endometrial Stromal / drug therapy. Sarcoma, Endometrial Stromal / metabolism. Sarcoma, Endometrial Stromal / pathology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19767065.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0 / Receptors, Estrogen
  •  go-up   go-down


26. Leung F, Terzibachian JJ, Aouar Z, Govyadovskiy A, Lassabe C: [Uterine sarcomas: clinical and histopathological aspects. Report on 15 cases]. Gynecol Obstet Fertil; 2008 Jun;36(6):628-35
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Uterine sarcomas: clinical and histopathological aspects. Report on 15 cases].
  • [Transliterated title] Sarcomes utérins: aspects cliniques et histopathologiques. A propos de 15 cas.
  • OBJECTIVE: Sarcoma of the uterus are rare uterine cancers with poor prognosis.
  • The aim of this study was to review our experience with uterine sarcomas, to analyze their clinical and histopathological features, to discuss about diagnostic and therapeutic difficulties associated with these tumours and to compare our findings with previously published data.
  • PATIENTS AND METHODS: A retrospective review, from 1996 to 2005, of cases of uterine sarcomas diagnosed and treated at the department of obstetrics-gynaecology, Belfort Hospital.
  • Clinical and pathological features, types of treatment, tumoral stage according to the FIGO histological classification and patients' outcome were recorded.
  • RESULTS: From 1996 to 2005, 15 cases of uterine sarcomas have been diagnosed in our department.
  • Our study included six histological types: carcinosarcoma (n=5), leiomyosarcoma (n=3), rhabdomyosarcoma (n=2), adenosarcoma (n=2), stromal sarcoma (n=2), and undifferentiated sarcoma (n=1).
  • Patients' mean age at the time of diagnosis was 67.6 years (range: 48-91 years).
  • The mean time from onset of symptomatology and pathological diagnosis of sarcoma was 17.1 weeks (range: one to 60 weeks).
  • In 10 patients (67%), definitive diagnosis of sarcoma was achieved only after surgical specimen analysis and in only three of them (30%), physical examination combined with pelvic ultrasonography had suspected malignancy.
  • Six patients benefited from adjuvant treatment: external beam radiotherapy and brachytherapy in three cases, brachytherapy in one case and chemotherapy in two cases.
  • At the time of analysis, four patients were lost to follow-up, four patients were dead and with an average follow-up of 25 months, seven patients had a favourable outcome.
  • DISCUSSION AND CONCLUSION: Uterine sarcomas are rare cancers with poor prognosis.
  • Early diagnosis is essential because patients' survival is correlated to tumour stage.
  • However, preoperative diagnosis is often difficult and definitive diagnosis is frequently achieved after pathological analysis of hysterectomies specimens.
  • [MeSH-major] Chemotherapy, Adjuvant. Hysterectomy / methods. Ovariectomy / methods. Radiotherapy, Adjuvant. Sarcoma / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538624.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


27. Rovirosa A, Ascaso C, Ordi J, Arenas M, Valduvieco I, Lejarcegui JA, Pahisa J, Torne A, Biete A: How to deal with prognostic factors and radiotherapy results in uterine neoplasms with a sarcomatous component? Clin Transl Oncol; 2009 Oct;11(10):681-7
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How to deal with prognostic factors and radiotherapy results in uterine neoplasms with a sarcomatous component?
  • PURPOSE: Uterine tumours with a sarcomatous component are rare neoplasms with a wide pathologic heterogeneity in which the stage is the main prognostic factor.
  • METHODS AND MATERIALS: Eighty-one patients diagnosed and treated for uterine tumours with a sarcomatous component at the Hospital Clinic in Barcelona between 1975 and 2003 were retrospectively studied; 76/81 patients underwent surgery (total hysterectomy plus bilateral salpingo-oophorectomy, and in 13/76 of these patients an additional pelvic lymphadenectomy was performed).
  • 5/81 patients received complementary chemotherapy to the surgery and 5 patients received chemotherapy as treatment of local and distant relapse (All the patients were treated with a different chemotherapy schedule).
  • For pathological type the frequency by advanced vs. early stages was 54% vs. 52% for carcinosarcomas, 33.5% vs. 17.5% for leiomyosarcoma, and 30.5% and 12.5% for adenosarcoma and endometrial stromal sarcoma, respectively.
  • CONCLUSIONS: Uterine tumours with a sarcomatous component have a poor outcome in spite of treatment in comparison to endometrial carcinoma, probably due to the higher frequency of adverse prognostic factors.
  • [MeSH-major] Carcinosarcoma / radiotherapy. Leiomyosarcoma / radiotherapy. Uterine Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1240-5 [3897471.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Feb;65(2):129-42 [17706430.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):70-5 [9345359.001]
  • [Cites] Cancer. 1993 Feb 15;71(4 Suppl):1702-9 [8381710.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):191-6 [15262141.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1320-9 [11955745.001]
  • [Cites] Eur J Cancer. 1991;27(9):1095-9 [1835616.001]
  • [Cites] Eur J Surg Oncol. 2007 Feb;33(1):91-5 [17174517.001]
  • [Cites] AJR Am J Roentgenol. 1976 Jan;126(1):139-47 [175673.001]
  • [Cites] Gynecol Oncol. 1996 Jul;62(1):25-32 [8690287.001]
  • [Cites] Cancer. 2000 Jun 15;88(12):2782-6 [10870061.001]
  • [Cites] Gynecol Oncol. 1999 Aug;74(2):196-201 [10419731.001]
  • [Cites] Eur J Cancer. 2008 Apr;44(6):808-18 [18378136.001]
  • [Cites] Histopathology. 2004 May;44(5):472-9 [15139995.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1366-73 [14630275.001]
  • [Cites] Gynecol Oncol. 1989 Sep;34(3):372-8 [2548936.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1425-31 [10717626.001]
  • [Cites] Gynecol Oncol. 1997 Apr;65(1):158-63 [9103406.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):204-8 [15047237.001]
  • [Cites] Med Clin (Barc). 1998 Jul 11;111(5):172-6 [9732833.001]
  • [Cites] Br J Radiol. 1993 Nov;66(791):1009-15 [8281375.001]
  • [Cites] Oncology. 1988;45(6):428-33 [3186152.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):624-37 [15863170.001]
  • [Cites] Br J Obstet Gynaecol. 1992 Jul;99(7):590-4 [1326319.001]
  • [Cites] Gynecol Oncol. 1999 Feb;72(2):232-7 [10021306.001]
  • (PMID = 19828411.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


28. Caceres A, Mourton SM, Bochner BH, Gerst SR, Liu L, Alektiar KM, Kardos SV, Barakat RR, Boland PJ, Chi DS: Extended pelvic resections for recurrent uterine and cervical cancer: out-of-the-box surgery. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):1139-44
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended pelvic resections for recurrent uterine and cervical cancer: out-of-the-box surgery.
  • Patients with recurrent uterine and cervical cancer have poor prognoses.
  • The objective of this study was to analyze the outcomes of patients with recurrent uterine and cervical cancer who had undergone attempted curative resection of pelvic bone, sidewall muscle, major blood vessels, and/or nerves.
  • We reviewed the records of all 14 patients with recurrent uterine and cervical cancer who had extended pelvic resections at our institution between June 2000 and November 2006.
  • Primary sites of disease were the uterus (11 patients) and cervix (3 patients).
  • Tumor histology was as follows: adenocarcinoma, seven; squamous cell carcinoma, three; leiomyosarcoma, three; and adenosarcoma, one.
  • Previous treatment included hysterectomy, 11; pelvic radiation, 9; chemotherapy, 9; and total pelvic exenteration, 2.
  • Seven patients (50%) received high-dose rate intraoperative radiation therapy.
  • Median total operating time was 628 min (range, 345-935 min) and median estimated blood loss was 900 mL (range, 300-16,000 mL).
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Pelvic Exenteration. Uterine Cervical Neoplasms / surgery


29. Rovirosa A, Ascaso C, Ordi J, Abellana R, Arenas M, Lejarcegui JA, Pahisa J, Puig-Tintoré LM, Mellado B, Armenteros B, Iglesias X, Biete A: Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages. Int J Radiat Oncol Biol Phys; 2002 Apr 1;52(5):1320-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages.
  • BACKGROUND: Sarcomatous neoplasms of the uterine corpus are still a challenge in terms of obtaining prognostic factors and the most optimum complementary treatment to surgery.
  • METHODS: Sixty patients diagnosed with uterine neoplasms with a main sarcomatous component were treated at Hospital Clínic i Universitari of Barcelona between January 1975 and June 1999.
  • Pathologic type: 32 carcinosarcomas, 14 leiomyosarcomas, 9 adenosarcomas, and 5 endometrial stromal sarcomas.
  • TREATMENT: 58/60 surgery, 35/60 postoperative radiotherapy, 2/60 exclusive chemotherapy, and 3/60 complementary chemotherapy.
  • STATISTICS: the S and Cox proportional risk models.
  • Only leiomyosarcoma type made the overall survival worse (HR = 10.54).
  • Nevertheless, prospective studies are still needed on prognostic factors and on the best treatment option.
  • [MeSH-major] Sarcoma / mortality. Sarcoma / pathology. Uterine Neoplasms / mortality. Uterine Neoplasms / pathology
  • [MeSH-minor] Adenosarcoma / mortality. Adenosarcoma / pathology. Adenosarcoma / secondary. Adult. Aged. Aged, 80 and over. Carcinosarcoma / mortality. Carcinosarcoma / pathology. Carcinosarcoma / secondary. Female. Humans. Leiomyosarcoma / mortality. Leiomyosarcoma / pathology. Leiomyosarcoma / secondary. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11955745.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Garuti G, Cellani F, Centinaio G, Montanari G, Nalli G, Luerti M: Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors. Gynecol Oncol; 2006 Nov;103(2):599-603
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: A prospective evaluation of the effects on endometrium of third generation aromatase inhibitors (AIs), administered as adjuvant up-front therapy or switched therapy in menopausal patients suffering from breast cancer.
  • METHODS: Forty-five patients suffering from estrogen-receptor positive breast cancer were treated with AIs as adjuvant endocrine therapy; 27 patients switched from tamoxifen to AIs (group 1) due to adverse medical events related to tamoxifen intake (22 patients) or to an extended endocrine treatment after 60 months of tamoxifen therapy (5 patients); whereas 18 patients received AIs as up-front adjuvant therapy (group 2).
  • All patients underwent endometrial investigation before the start of AIs therapy and, thereafter, at 12 month intervals.
  • Endometrial assessment was based on Transvaginal Ultrasonography (TU), followed by hysteroscopy and endometrial biopsy when a double layered endometrial stripe above 4 mm was measured on the longitudinal plane of uterine scanning.
  • Six patients, showing endometrial hyperplasia before the start of AIs therapy, underwent hysteroscopy on a yearly basis, disregarding the endometrial thickness measured by TU.
  • RESULTS: Demographic and clinical variables evaluated (age, parity, age at menarche and menopause, Body Mass Index, previous chemotherapy and radiotherapy) did not differ in groups 1 and 2.
  • The average period of endometrial surveillance after the start of AIs therapy was 24.8 +/-10.8 months for group 1 and 21.4 +/- 11.5 months for group 2.
  • A progressive decrease of endometrial thickness, from 8.2 +/- 5.0 to 3.0 +/- 1.2 in group 1 and from 4.7 +/- 4.3 to 1.9 +/- 0.3 in group 2, was found before the start and after 36-48 months of AIs therapy.
  • The second line endometrial investigations' rate dropped from 70.3% to 12.5% in group 1 and from 27.7% to 0.0% in group 2, at baseline and after 36-48 months of AIs therapy, respectively.
  • Only in 1 patient (2.2%) of group 2 did we find an emerging pathology, consisting of adenosarcoma harbored within an endometrial polyp, detected after 12 months of therapy with letrozole.
  • In 3 out of 5 patients showing simple hyperplasia and in 1 patient showing atypical hyperplasia before the start of AIs therapy, we observed a reversal to normal endometrium and to simple hyperplasia, respectively, after 12 months of therapy with anastrozole.
  • CONCLUSIONS: AIs delivered as up-front therapy for breast cancer have no effects on unspecific endometrial thickening.
  • When administered as switched therapy after tamoxifen withdrawal, AIs may reverse tamoxifen-associated endometrial thickening.
  • A low rate of emerging endometrial pathology was found during AIs therapy.
  • [MeSH-major] Aromatase Inhibitors / adverse effects. Breast Neoplasms / drug therapy. Endometrial Hyperplasia / chemically induced. Endometrium / drug effects
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Humans. Menopause. Middle Aged. Prospective Studies. Tamoxifen / adverse effects. Tamoxifen / therapeutic use

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750259.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


31. Le Bouëdec G, Penault-Llorca F, de Latour M, Tortochaux J, Dauplat J: [Mixed müllerian tumours of the endometrium. About four cases developed on tamoxifen treatment]. Gynecol Obstet Fertil; 2003 Sep;31(9):733-8
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mixed müllerian tumours of the endometrium. About four cases developed on tamoxifen treatment].
  • [Transliterated title] Tumeurs mixtes müllériennes de l'endomètre. A propos de quatre cas développés sous tamoxifène.
  • Various histopathologic features were encountered: one müllerian adenosarcoma and three malignant mixed müllerian tumors so called carcinosarcomas (in one case the sarcomatous component was homologous composed of tissues normally found in the uterus, while the others were heterologous because they were containing some elements normally not found in the uterus).
  • Concern has been raised about prolonged tamoxifen treatment and subsequent occurrence of endometrial adenocarcinoma.
  • Then, attention has been drawn through high-risk histologic subtypes including poorly differentiated patterns, uterine sarcomas and such mixed müllerian tumors.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Endometrial Neoplasms / chemically induced. Mixed Tumor, Mullerian / chemically induced. Tamoxifen / adverse effects
  • [MeSH-minor] Aged. Aged, 80 and over. Breast Neoplasms / drug therapy. Female. Humans. Middle Aged. Postmenopause

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Obstet Fertil. 2004 Dec;32(12):1091-2 [15589790.001]
  • (PMID = 14499719.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


32. Jessop FA, Roberts PF: Müllerian adenosarcoma of the uterus in association with tamoxifen therapy. Histopathology; 2000 Jan;36(1):91-2
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Müllerian adenosarcoma of the uterus in association with tamoxifen therapy.
  • [MeSH-major] Adenosarcoma / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Mullerian Ducts / drug effects. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10681194.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


33. Chourmouzi D, Boulogianni G, Zarampoukas T, Drevelengas A: Sonography and MRI of tamoxifen-associated müllerian adenosarcoma of the uterus. AJR Am J Roentgenol; 2003 Dec;181(6):1673-5
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonography and MRI of tamoxifen-associated müllerian adenosarcoma of the uterus.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Mixed Tumor, Mullerian / chemically induced. Mixed Tumor, Mullerian / diagnosis. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Endosonography. Female. Humans. Magnetic Resonance Imaging. Middle Aged

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14627594.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


34. Mhawech P, Vlastos AT, Pelte MF: Pathologic quiz case. Uterine polypoid mass in a postmenopausal patient following tamoxifen treatment for breast cancer. Arch Pathol Lab Med; 2002 Sep;126(9):1125-6
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic quiz case. Uterine polypoid mass in a postmenopausal patient following tamoxifen treatment for breast cancer.
  • [MeSH-major] Adenosarcoma / pathology. Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Mullerian Ducts / pathology. Tamoxifen / therapeutic use. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12240628.001).
  • [ISSN] 0003-9985
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down






Advertisement